High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes

[1] DeFronzo RA(2015)Type 2 diabetes mellitus Nat Rev Dis Primers 1 15019-324

[2] Ferrannini E(2013)Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables BMC Publ Health 13 602-S110

[3] Groop L(2019)Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition Diabetes Res Clin Pract 157 107843-1705

[4] Henry RR(2016)Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis JAMA 316 313-1528

[5] Herman WH(2020)Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020 Diabetes Care 43 S98-311

[6] Holst JJ(2006)The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696-84

[7] Ji LN(2011)GLP-1 receptor agonists and HbA1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials Curr Med Res Opin 27 1519-149

[8] Lu JM(2014)FGF21-based pharmacotherapy–potential utility for metabolic disorders Trends Endocrinol Metab 25 303-2115

[9] Guo XH(2019)Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output EBioMedicine 41 73-1000

[10] Yang WY(2014)Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice Biomed Res Int 2014 751930-795

[1] DeFronzo RA(2015)Type 2 diabetes mellitus Nat Rev Dis Primers 1 15019-324

[2] Ferrannini E(2013)Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables BMC Publ Health 13 602-S110

[3] Groop L(2019)Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition Diabetes Res Clin Pract 157 107843-1705

[4] Henry RR(2016)Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis JAMA 316 313-1528

[5] Herman WH(2020)Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020 Diabetes Care 43 S98-311

[6] Holst JJ(2006)The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696-84

[7] Ji LN(2011)GLP-1 receptor agonists and HbA1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials Curr Med Res Opin 27 1519-149

[8] Lu JM(2014)FGF21-based pharmacotherapy–potential utility for metabolic disorders Trends Endocrinol Metab 25 303-2115

[9] Guo XH(2019)Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output EBioMedicine 41 73-1000

[10] Yang WY(2014)Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice Biomed Res Int 2014 751930-795